Author Archives: Modulight

ISO 27001 – information security standard for Modulight

February 28, 2024 by Modulight
No comments
Modulight achieved the international ISO 27001 information security standard certification today on February 28, 2024. The certification of the information security management system demonstrates the organization’s commitment to protecting information and managing high-level of information security. “We are expanding the use of cloud services in accordance with our SaaS business model and are making strong progress in transitioning to a pay-per-treatment (PPT) payment model. Managing patient information requires very high-level information security processes, which is why we started to pursue the ISO 27001 certification in Continue reading →Modulight achieved the international ISO 27001 information security standard certification today on February 28, 2024. The certification of the information security management system demonstrates the organization's commitment to protecting information and managing high-level of information security. "We are expanding the use of cloud services in accordance with our SaaS business model and are making strong progress in transitioning to a pay-per-treatment (PPT) payment model. Managing patient information requires very high-level information security processes, which is why we started to pursue the ISO 27001 certification in Continue reading →

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

February 6, 2024 by Modulight
No comments
Published in: Cell & Bioscience Authors: Aaron Sorrin, Anika Dasgupta, Kathryn McNaughton, Carla Arnau Del Valle, Keri Zhou, Cindy Liu, Dana M. Roque & Huang Chiao Huang Within the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired with photodynamic therapy (PDT), which involves light-activation of specialized dyes (photosensitizers) to stimulate cancer cell death through reactive oxygen species generation. In this study, a novel combination strategy was Continue reading →

Pharmaceutical nanotechnology applied to phthalocyanines for the promotion of antimicrobial photodynamic therapy: A literature review

September 1, 2022 by Modulight
No comments
Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior  Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior   Phthalocyanines are photosensitizers activated by light at a specific wavelength in the presence of oxygen and act through the production of Reactive Oxygen Species, which simultaneously attack several biomolecular targets in the pathogen agent and, therefore, have multiple and variable action sites. This nonspecific action site bypasses conventional resistance mechanisms. Antimicrobial Photodynamic Therapy (aPDT) is Continue reading →

Towards Photodynamic Image-Guided Surgery of Head and Neck Tumors: Photodynamic Priming Improves Delivery and Diagnostic Accuracy of Cetuximab-IRDye800CW

June 28, 2022 by Modulight
No comments
Published in: Frontiers in Oncology Authors: Chanda Bhandari, John Fakhry, Menitte Eroy, Jane Junghwa Song, Kimberley Samkoe, Tayyaba Hasan, Kenneth Hoyt, Girgis Obaid    Published in: Frontiers in Oncology Authors: Chanda Bhandari, John Fakhry, Menitte Eroy, Jane Junghwa Song, Kimberley Samkoe, Tayyaba Hasan, Kenneth Hoyt, Girgis Obaid   The study showed that photodynamic priming (subtherapeutic doses of light using ML6500) of tumor microenvironment with nanoliposomal BPD is highly beneficial for delivery of antibodies (Cet-IR800) to H&N tumor in mice. Priming significantly improved the tumor accumulation of Cet-IR800 and diagnostic accuracy of tumor detection, as monitored with fluroescence imaging.   Read the article here

Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives

April 15, 2022 by Modulight
No comments
Simple Summary Photodynamic therapy (PDT) is a light-activated treatment modality, which is being clinically used and further developed for a number of premalignancies, solid tumors, and disseminated cancers. Nanomedicines that facilitate PDT (photonanomedicines, PNMs) have transformed its safety, efficacy, and capacity for multifunctionality. This review focuses on the state of the art in deep-tissue activation technologies for PNMs and explores how their preclinical use can evolve towards clinical translation by harnessing current clinically available instrumentation.Simple Summary Photodynamic therapy (PDT) is a light-activated treatment modality, which is being clinically used and further developed for a number of premalignancies, solid tumors, and disseminated cancers. Nanomedicines that facilitate PDT (photonanomedicines, PNMs) have transformed its safety, efficacy, and capacity for multifunctionality. This review focuses on the state of the art in deep-tissue activation technologies for PNMs and explores how their preclinical use can evolve towards clinical translation by harnessing current clinically available instrumentation. Read article

Tamperelainen teknologiayritys Modulight kertoo saaneensa tilauksen suurelta lääkeyhtiöltä – tuotteita aiotaan käyttää keuhkosyöpätutkimuksessa

April 1, 2022 by Modulight
No comments
Modulightin tuotteita hyödynnetään uusia hoitomenetelmiä keuhkosyöpään etsivässä tutkimusprojektissa, yritys kertoo. Tamperelainen biolääketieteen alan yritys Modulight kertoi torstaina saaneensa tilauksen maailman viiden suurimman lääkealan yhtiön joukkoon kuuluvalta lääkeyhtiöltä.Modulightin tuotteita hyödynnetään uusia hoitomenetelmiä keuhkosyöpään etsivässä tutkimusprojektissa, yritys kertoo. Tamperelainen biolääketieteen alan yritys Modulight kertoi torstaina saaneensa tilauksen maailman viiden suurimman lääkealan yhtiön joukkoon kuuluvalta lääkeyhtiöltä. Read article

Ophthalmic laser platform utilizing AI to enhance treatment planning of liposomal drug release

March 7, 2022 by Modulight
No comments
Presented in: SPIE BIOS 2022 Authors: Eero Koivumäki, Laura Vesala, Jukka-Pekka Alanko, Timo Tanila, Petteri Uusimaa, Modulight Corporation (Finland)    Presented in: SPIE BIOS 2022 Authors: Eero Koivumäki, Laura Vesala, Jukka-Pekka Alanko, Timo Tanila, Petteri Uusimaa, Modulight Corporation (Finland)   Delivery of pharmaceuticals to the eye posterior poses a major challenge in ophthalmology. A promising drug delivery platform is indocyanine green (ICG) liposomes, which absorb near-infrared light resulting in a release of pharmaceutical molecules. The Modulight ophthalmic laser platform has been designed for treatments targeting the eye posterior and can also excite the absorption band of the liposomes. The laser connects with Modulight Cloud, enabling Continue reading →

Configurable multi-wavelength laser light engine for endoscopic fluorescence imaging

March 3, 2022 by Modulight
No comments
Presented in: SPIE BIOS 2022 Authors: Zoe Ylöniemi, Visa Kaivosoja, Lasse Orsila, Tero Vierimaa, Petteri Uusimaa, Modulight Corporation (Finland)    Presented in: SPIE BIOS 2022 Authors: Zoe Ylöniemi, Visa Kaivosoja, Lasse Orsila, Tero Vierimaa, Petteri Uusimaa, Modulight Corporation (Finland)   Using different fluorescent dyes for clinical applications need endoscopic illumination sources with multiple wavelengths. Fluorescent imaging with simultaneous white light overlay image benefit from laser light sources for fluorescence excitation and white light illumination to allow for easy spectral filtering on imaging side. Imaging of complementary fluorescent dyes adds requirements for the light source. Modulight ML7710 oncology laser platform was developed to fulfill the requirements Continue reading →

Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer

February 25, 2022 by Modulight
No comments
Published in: Biomedicines Authors: Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya    Published in: Biomedicines Authors: Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya   Blue light cystoscopy/Photodynamic diagnosis (PDD) was shown in rat models of bladder cancer to not only help in visualization and better removal of tumors, but also lead to anti-tumor effects and stimulation of immune system. ML6500 was used as blue light source for PDD.   Read the article here

CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model

January 4, 2022 by Modulight
No comments
Published in: OncoImmunology Authors: Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi    Published in: OncoImmunology Authors: Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   The study aimed to develop photoimmunotherapy for pigmented melanoma, which can challenging indication since the pigment could absorb light and make treatment ineffective. In vitro & in vivo studies with ML7710 laser compared PIT against pigmented and non-pigmented melanoma and found no differences. CD29 targeted PIT was more effective than CD44 targeted PIT, relating to expression of CD44 on Continue reading →